PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

Ajay K. Gopal, Brad S. Kahl, Svende Vos, Nina D. Wagner-Johnston, Stephen J. Schuster, Wojciech J. Jurczak, Ian W. Flinn, Christopher R. Flowers, Peter Martin, Andreas Viardot, Kristie A. Blum, Andre H. Goy, Andrew J. Davies, Pier Luigi Zinzani, Martin Dreyling, Dave Johnson, Langdon L. Miller, Leanne Holes, Daniel Li, Roger D. DanseyWayne R. Godfrey, Gilles A. Salles

Research output: Contribution to journalArticlepeer-review

911 Scopus citations


BACKGROUND: Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas. METHODS: In this single-group, open-label, phase 2 study, 125 patients with indolent non-Hodgkin's lymphomas who had not had a response to rituximab and an alkylating agent or had had a relapse within 6 months after receipt of those therapies were administered idelalisib, 150 mg twice daily, until the disease progressed or the patient withdrew from the study. The primary end point was the overall rate of response; secondary end points included the duration of response, progression-free survival, and safety. RESULTS: The median age of the patients was 64 years (range, 33 to 87); patients had received a median of four prior therapies (range, 2 to 12). Subtypes of indolent non-Hodgkin's lymphoma included follicular lymphoma (72 patients), small lymphocytic lymphoma (28), marginal-zone lymphoma (15), and lymphoplasmacytic lymphoma with or without Waldenström's macroglobulinemia (10). The response rate was 57% (71 of 125 patients), with 6% meeting the criteria for a complete response. The median time to a response was 1.9 months, the median duration of response was 12.5 months, and the median progression-free survival was 11 months. Similar response rates were observed across all subtypes of indolent non-Hodgkin's lymphoma, though the numbers were small for some categories. The most common adverse events of grade 3 or higher were neutropenia (in 27% of the patients), elevations in aminotransferase levels (in 13%), diarrhea (in 13%), and pneumonia (in 7%). CONCLUSIONS: In this single-group study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment.

Original languageEnglish
Pages (from-to)1008-1018
Number of pages11
JournalNew England Journal of Medicine
Issue number11
StatePublished - 2014


Dive into the research topics of 'PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma'. Together they form a unique fingerprint.

Cite this